Gaviria-Mendoza Andrés, Machado-Duque Manuel Enrique, Valladales-Restrepo Luis Fernando, Tovar-Yepes Carlos Fernando, Machado-Alba Jorge Enrique
Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnologica de Pereira-Audifarma S.A, Calle 105 No. 14-140, Pereira, Risaralda, Colombia.
Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Ave Las Americas #98-56, Pereira, Colombia.
Int J Vasc Med. 2022 Sep 21;2022:3045942. doi: 10.1155/2022/3045942. eCollection 2022.
Many of the therapeutic proposals for COVID-19 have been associated with adverse effects, including the risk of QT interval prolongation and torsades de pointes (TdP). The objective was to determine the use of drugs with a risk of QT interval prolongation in 21 clinics/hospitals in Colombia from January to December 2020.
This cross-sectional study identified drug use according to pharmacological groups with potential risk of QT interval prolongation according to a risk classification: conditional, possible, and known risk of TdP. Descriptive analyses were performed.
A total of 355,574 patients who received QT-prolonging drugs were identified (equivalent to 51.4% of all inpatients treated during the study period). Of the group of patients on QT drugs, 54.4% used at least one drug with conditional risk, 52.6% with possible risk, and 40.3% with known risk. The most commonly used belonged to the group of drugs for the nervous system (63.0%), alimentary tract and metabolism (56.8%), anti-infectives for systemic use (13.0%), and the cardiovascular system (11.7%). On average, patients received 2.0 ± 1.5 risk drugs. Regarding drugs initially considered against COVID-19, 2,120 patients (0.6%) received azithromycin, 802 (0.2%) received chloroquine, 517 received hydroxychloroquine (0.1%), and 265 received lopinavir/ritonavir (0.1%).
The high proportion of patients treated at the hospital level who receive drugs with risk of prolonging the QT interval should alert those responsible for their care to avoid fatal outcomes, especially during the COVID-19 epidemic, when some QT drugs are being used more frequently.
许多针对2019冠状病毒病（COVID-19）的治疗方案都伴有不良反应，包括QT间期延长和尖端扭转型室速（TdP）风险。目的是确定2020年1月至12月哥伦比亚21家诊所/医院中使用有QT间期延长风险药物的情况。
这项横断面研究根据药理学分组确定药物使用情况，依据风险分类：有条件、可能以及已知TdP风险，对QT间期延长潜在风险进行评估。进行描述性分析。
共识别出355574例接受延长QT间期药物治疗的患者（相当于研究期间所有住院患者的51.4%）。在使用QT药物的患者组中，54.4%使用至少一种有条件风险的药物，52.6%使用可能有风险的药物，40.3%使用已知有风险的药物。最常用的药物属于神经系统药物组（63.0%）、消化道和代谢药物组（56.8%）、全身用抗感染药物组（13.0%）以及心血管系统药物组（11.7%）。患者平均接受2.0±1.5种有风险的药物。关于最初被认为用于治疗COVID-19的药物，2120例患者（0.6%）接受阿奇霉素，802例（0.2%）接受氯喹，517例接受羟氯喹（0.1%），265例接受洛匹那韦/利托那韦（0.1%）。
在医院接受有延长QT间期风险药物治疗的患者比例很高，这应提醒负责其治疗的人员避免出现致命后果，尤其是在COVID-19疫情期间，此时一些QT药物的使用更为频繁。
